Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 439

1.

Cardiac Snail family of transcription factors directs systemic lipid metabolism in Drosophila.

Liu Y, Bao H, Wang W, Lim HY.

PLoS Genet. 2019 Nov 14;15(11):e1008487. doi: 10.1371/journal.pgen.1008487. [Epub ahead of print]

2.

Global coagulation assays in patients with multiple myeloma and monoclonal gammopathy of unknown significance.

Lim HY, Brook R, Krishnamoorthi B, Tacey M, Leung T, Donnan G, Nandurkar H, Ho P.

Thromb Res. 2019 Oct 20;183:45-48. doi: 10.1016/j.thromres.2019.10.017. [Epub ahead of print] No abstract available.

PMID:
31669660
3.

Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).

Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL.

Eur J Cancer. 2019 Oct 24. pii: S0959-8049(19)30727-0. doi: 10.1016/j.ejca.2019.08.034. [Epub ahead of print]

PMID:
31668839
4.

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients.

Bray SM, Lee J, Kim ST, Hur JY, Ebert PJ, Calley JN, Wulur IH, Gopalappa T, Wong SS, Qian HR, Ting JC, Liu J, Willard MD, Novosiadly RD, Park YS, Park JO, Lim HY, Kang WK, Aggarwal A, Kim HC, Reinhard C.

Sci Rep. 2019 Oct 25;9(1):15365. doi: 10.1038/s41598-019-51981-5.

5.

Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists.

Eeda V, Wu D, Lim HY, Wang W.

Bioorg Med Chem Lett. 2019 Nov 15;29(22):126664. doi: 10.1016/j.bmcl.2019.126664. Epub 2019 Sep 3.

PMID:
31591015
6.

Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer.

Yoo GS, Park HC, Yu JI, Choi DH, Cho WK, Park YS, Park JO, Lim HY, Kang WK, Lee WY, Kim HC, Yun SH, Cho YB, Park YA, Song KD, Kim SH, Ha SY.

Cancer Res Treat. 2019 Sep 25. doi: 10.4143/crt.2019.261. [Epub ahead of print]

7.

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma.

Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, Choi C, Park HC.

Cancer Med. 2019 Nov;8(16):6986-6994. doi: 10.1002/cam4.2570. Epub 2019 Oct 7.

8.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Oct 1. doi: 10.1158/2159-8290.CD-19-0555. [Epub ahead of print]

PMID:
31575541
9.

Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (≤45 Years) With Gastric Cancer.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Lim HY, Kim ST, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim HS, Ahn S.

Anticancer Res. 2019 Oct;39(10):5811-5820. doi: 10.21873/anticanres.13785.

PMID:
31570486
10.

Real-World Direct Oral Anticoagulants Experience in Atrial Fibrillation: Falls Risk and Low Dose Anticoagulation are Predictive of both Bleeding and Stroke Risk.

Brook R, Aswapanyawongse O, Tacey M, Kitipornchai T, Ho P, Lim HY.

Intern Med J. 2019 Sep 30. doi: 10.1111/imj.14640. [Epub ahead of print]

PMID:
31566857
11.

Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification.

Kim ST, Lee IK, Rom E, Sirkis R, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Yayon A, Lee J.

Am J Transl Res. 2019 Jul 15;11(7):4508-4515. eCollection 2019.

12.

Select Septate Junction Proteins Direct ROS-Mediated Paracrine Regulation of Drosophila Cardiac Function.

Lim HY, Bao H, Liu Y, Wang W.

Cell Rep. 2019 Aug 6;28(6):1455-1470.e4. doi: 10.1016/j.celrep.2019.07.004.

13.

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.

Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, Odegaard JI, Harrington EA, Lee J, Lee T, Oh SY, Kang JH, Kim JH, Kim Y, Ji JH, Kim YS, Lee KE, Kim J, Sohn TS, An JY, Choi MG, Lee JH, Bae JM, Kim S, Kim JJ, Min YW, Min BH, Kim NKD, Luke S, Kim YH, Hong JY, Park SH, Park JO, Park YS, Lim HY, Talasaz A, Hollingsworth SJ, Kim KM, Kang WK.

Cancer Discov. 2019 Oct;9(10):1388-1405. doi: 10.1158/2159-8290.CD-19-0442. Epub 2019 Jul 17.

PMID:
31315834
14.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.

Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

J Cancer. 2019 Jun 2;10(14):3140-3144. doi: 10.7150/jca.30355. eCollection 2019.

15.

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target.

Lee SJ, Byeon SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lim HY, Kim KM, Kim ST.

J Immunother. 2019 Oct;42(8):279-283. doi: 10.1097/CJI.0000000000000283.

PMID:
31219974
16.

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.

Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

J Cancer. 2019 Mar 3;10(7):1611-1615. doi: 10.7150/jca.29106. eCollection 2019.

17.

Reporting of randomized controlled trials in International Journal of Obstetric Anesthesia.

Lim HY, Kim KN, Jun JH, Lee SW, Kang MS.

Int J Obstet Anesth. 2019 Apr 16. pii: S0959-289X(18)30371-6. doi: 10.1016/j.ijoa.2019.04.006. [Epub ahead of print] No abstract available.

PMID:
31204097
18.

Protective Function of Mitogen-Activated Protein Kinase Phosphatase 5 in Aging- and Diet-Induced Hepatic Steatosis and Steatohepatitis.

Tang P, Low HB, Png CW, Torta F, Kumar JK, Lim HY, Zhou Y, Yang H, Angeli V, Shabbir A, Tai ES, Flavell RA, Dong C, Wenk MR, Yang DY, Zhang Y.

Hepatol Commun. 2019 Mar 1;3(6):748-762. doi: 10.1002/hep4.1324. eCollection 2019 Jun.

19.

A review of global coagulation assays - Is there a role in thrombosis risk prediction?

Lim HY, O'Malley C, Donnan G, Nandurkar H, Ho P.

Thromb Res. 2019 Jul;179:45-55. doi: 10.1016/j.thromres.2019.04.033. Epub 2019 May 1. Review.

PMID:
31078120
20.

In-situ local phase-transitioned MoSe2 in La0.5Sr0.5CoO3-δ heterostructure and stable overall water electrolysis over 1000 hours.

Oh NK, Kim C, Lee J, Kwon O, Choi Y, Jung GY, Lim HY, Kwak SK, Kim G, Park H.

Nat Commun. 2019 Apr 12;10(1):1723. doi: 10.1038/s41467-019-09339-y.

21.

Classification, bacteriological findings, and analysis of sex hormone receptors and cytokine expression in mammary lesions of abattoir sows.

Ju JH, Shin JI, Lim HY, Kim HW, Seung BJ, Cho SH, Kim SH, Sur JH.

J Vet Sci. 2019 Mar;20(2):e11. doi: 10.4142/jvs.2019.20.e11. Epub 2019 Mar 15.

22.

Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches.

Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, Zhang XM, Foo S, Nakamizo S, Duan K, Kong WT, Gentek R, Balachander A, Carbajo D, Bleriot C, Malleret B, Tam JKC, Baig S, Shabeer M, Toh SES, Schlitzer A, Larbi A, Marichal T, Malissen B, Chen J, Poidinger M, Kabashima K, Bajenoff M, Ng LG, Angeli V, Ginhoux F.

Science. 2019 Mar 15;363(6432). pii: eaau0964. doi: 10.1126/science.aau0964.

PMID:
30872492
23.

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.

Kim ST, Kang JH, Lee J, Lee HW, Oh SY, Jang JS, Lee MA, Sohn BS, Yoon SY, Choi HJ, Hong JH, Kim MJ, Kim S, Park YS, Park JO, Lim HY.

Ann Oncol. 2019 May 1;30(5):788-795. doi: 10.1093/annonc/mdz058.

PMID:
30785198
24.

Small Molecule Modulators of the Circadian Molecular Clock With Implications for Neuropsychiatric Diseases.

Cha HK, Chung S, Lim HY, Jung JW, Son GH.

Front Mol Neurosci. 2019 Jan 21;11:496. doi: 10.3389/fnmol.2018.00496. eCollection 2018. Review.

25.

Loliolide Presents Antiapoptosis and Antiscratching Effects in Human Keratinocytes.

Park SH, Kim DS, Kim S, Lorz LR, Choi E, Lim HY, Hossain MA, Jang S, Choi YI, Park KJ, Yoon K, Kim JH, Cho JY.

Int J Mol Sci. 2019 Feb 2;20(3). pii: E651. doi: 10.3390/ijms20030651.

26.

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.

Kim ST, Lee S, Park M, Park SH, Park JO, Lim HY, Park YS, Kang WK, Gangolli EA, Shin H, Kim KM, Hollingsworth SJ, Mortimer PGS, Lee J.

Transl Oncol. 2019 Apr;12(4):597-601. doi: 10.1016/j.tranon.2018.12.009. Epub 2019 Jan 26.

27.

Effect of needle type on intravascular injection in transforaminal epidural injection: a meta-analysis.

Kim JY, Kim SN, Park C, Lim HY, Kim JH.

Korean J Pain. 2019 Jan;32(1):39-46. doi: 10.3344/kjp.2019.32.1.39. Epub 2019 Jan 2.

28.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
29.

Rapid and reliable identification of insulin 2 gene mutation in Akita diabetic mice by a tetra-primer-ARMS-PCR method.

Undi R, Lim HY, Wang W.

Heliyon. 2019 Jan 11;5(1):e01112. doi: 10.1016/j.heliyon.2018.e01112. eCollection 2019 Jan.

30.

Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients.

Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW.

PLoS One. 2019 Jan 14;14(1):e0210730. doi: 10.1371/journal.pone.0210730. eCollection 2019.

31.

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice.

Yoon SE, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Onco Targets Ther. 2018 Dec 24;12:225-231. doi: 10.2147/OTT.S187621. eCollection 2019.

32.

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial.

Kim Y, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Lee SJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

J Gastric Cancer. 2018 Dec;18(4):348-355. doi: 10.5230/jgc.2018.18.e34. Epub 2018 Nov 16.

33.

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.

Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31.

34.

Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.

Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley ER, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, Angeli V.

Immunity. 2018 Dec 18;49(6):1191. doi: 10.1016/j.immuni.2018.12.009. No abstract available.

PMID:
30566884
35.

Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.

Yoo C, Park JW, Kim YJ, Kim DY, Yu SJ, Lim TS, Lee SJ, Ryoo BY, Lim HY.

Invest New Drugs. 2019 Jun;37(3):567-572. doi: 10.1007/s10637-018-0707-5. Epub 2018 Dec 7.

PMID:
30523474
36.

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.

Oh SY, Lee S, Huh SJ, Lee J, Kim ST, Park SH, Lim HY, Kang WK, Kang BW, Kim JG, Lee HJ, Kim JH, Kang JH, Kim H.

Cancer Chemother Pharmacol. 2019 Mar;83(3):501-508. doi: 10.1007/s00280-018-3753-y. Epub 2018 Dec 8.

PMID:
30535535
37.

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.

Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK.

Cancer Res Treat. 2019 Jul;51(3):1128-1134. doi: 10.4143/crt.2018.379. Epub 2018 Nov 21.

38.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line.

Kim ST, Kim SY, Lee J, Kim K, Park SH, Park YS, Lim HY, Kang WK, Park JO.

BMC Cancer. 2018 Nov 12;18(1):1103. doi: 10.1186/s12885-018-4995-0.

39.

Comprehensive transcriptome analysis of Sarcophaga peregrina, a forensically important fly species.

Kim JY, Lim HY, Shin SE, Cha HK, Seo JH, Kim SK, Park SH, Son GH.

Sci Data. 2018 Nov 6;5:180220. doi: 10.1038/sdata.2018.220.

40.

A comparison of global coagulation assays between normal controls and patients with thrombocytopenia.

Lim HY, Leung P, Manitta V, Nandurkar H, Ho P.

Int J Lab Hematol. 2019 Apr;41(2):184-191. doi: 10.1111/ijlh.12941. Epub 2018 Oct 26.

PMID:
30365212
41.

Increased p63 Expression in Canine Perianal Gland Tumours.

Kim SH, Seung BJ, Cho SH, Lim HY, Park HM, Sur JH.

J Vet Res. 2018 Oct 24;62(2):229-235. doi: 10.2478/jvetres-2018-0020. eCollection 2018 Jun.

42.

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Yoo H, Kim K.

Cancer Res Treat. 2019 Jul;51(3):876-885. doi: 10.4143/crt.2018.401. Epub 2018 Oct 1.

43.

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation.

Lee T, Kim K, Lee J, Park SH, Park YS, Lim HY, Kang WK, Park JO, Kim ST.

J Cancer. 2018 Sep 8;9(18):3394-3399. doi: 10.7150/jca.26068. eCollection 2018.

44.

Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.

Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M.

Invest New Drugs. 2018 Dec;36(6):1072-1084. doi: 10.1007/s10637-018-0658-x. Epub 2018 Sep 10.

PMID:
30198057
45.

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial.

Lim SW, Lee S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.

J Cancer. 2018 Jul 30;9(16):2910-2915. doi: 10.7150/jca.24948. eCollection 2018.

46.

Expression of Oestrogen Receptor, Progesterone Receptor and Akt in Canine Circumanal Gland Tumours.

Kim SH, Seung BJ, Cho SH, Lim HY, Hwang JH, Sur JH.

J Comp Pathol. 2018 Jul;162:59-65. doi: 10.1016/j.jcpa.2018.06.006. Epub 2018 Jul 18.

PMID:
30060844
47.

Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.

Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley RE, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, Angeli V.

Immunity. 2018 Aug 21;49(2):326-341.e7. doi: 10.1016/j.immuni.2018.06.008. Epub 2018 Jul 24. Erratum in: Immunity. 2018 Dec 18;49(6):1191.

48.

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim HS, Ahn S.

Radiother Oncol. 2018 Nov;129(2):306-312. doi: 10.1016/j.radonc.2018.07.002. Epub 2018 Jul 20.

PMID:
30037498
49.

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK.

Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.

PMID:
30013197
50.

Effects of isometric, eccentric, or heavy slow resistance exercises on pain and function in individuals with patellar tendinopathy: A systematic review.

Lim HY, Wong SH.

Physiother Res Int. 2018 Oct;23(4):e1721. doi: 10.1002/pri.1721. Epub 2018 Jul 4. Review.

PMID:
29972281

Supplemental Content

Loading ...
Support Center